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Abstract: In Tunisia, there is a paucity of population-based data on Chronic Obstructive 
Pulmonary Disease (COPD) prevalence. To address this problem, we estimated  
the prevalence of COPD following the Burden of Lung Disease Initiative. We surveyed 
807 adults aged 40+ years and have collected information on respiratory history and 
symptoms, risk factors for COPD and quality of life. Post-bronchodilator spirometry was 
performed and COPD and its stages were defined according to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) guidelines. Six hundred and sixty one (661) 
subjects were included in the final analysis. The prevalence of GOLD Stage I and II or 
higher COPD were 7.8% and 4.2%, respectively (Lower Limit of Normal modified stage I 
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and II or higher COPD prevalence were 5.3% and 3.8%, respectively). COPD was more 
common in subjects aged 70+ years and in those with a BMI < 20 kg/m
2
. Prevalence of 
stage I+ COPD was 2.3% in <10 pack years smoked and 16.1% in 20+ pack years smoked. 
Only 3.5% of participants reported doctor-diagnosed COPD. In this Tunisian population, 
the prevalence of COPD is higher than reported before and higher than self-reported 
doctor-diagnosed COPD. In subjects with COPD, age is a much more powerful predictor of 
lung function than smoking.  
Keywords: COPD; prevalence; smoking; Tunisia; BOLD 
 
1. Introduction 
Chronic obstructive pulmonary disease (COPD) represents a major public health problem in 
developing countries and especially in North Africa [1]. It is characterized by lung function 
impairment with airway obstruction, and is currently estimated to be one of the leading causes of death 
in 2010 [2]. 
 
Although COPD is one of the leading causes of mortality and morbidity, epidemiological 
data on COPD are very limited in North Africa, including Tunisia. The comparison of the few 
Tunisian COPD prevalence estimates with the international literature showed that estimated 
prevalence of COPD in Tunisia was low compared with America and Europe and the disease is 
certainly under diagnosed
 
[1]. In fact, National estimates of COPD prevalence are usually based on 
self-reported diagnosis without the use of objective measurement of lung function by spirometry 
testing. One survey of chronic bronchitis has estimated the prevalence as 3.8% (1.1% in women and 
6.6% in men) [3].  
Several investigations, using spirometry, and conducted in the United States
 
[4], Korea
 
[5], Spain
 
[6], 
Sweden [7], and South America [8], have demonstrated the under-diagnosis of COPD. The most 
extreme example was observed in Japan, where the results of the 2004 population-based prevalence of 
COPD survey contrasts with the estimates of the Japanese Ministry of Health (10.9% vs. 0.3% 
respectively) [9]. Only 9.4% of the subjects documented with airflow obstruction reported a physician 
diagnosis of COPD. Similar rates of under diagnosis have been frequently reported [10]. 
Therefore, objective measurement of lung function by spirometry testing is needed to determine  
the true prevalence of COPD in Tunisia. The Burden of Obstructive Lung Disease (BOLD) study was 
designed to provide a standardized framework for estimating COPD prevalence, risk factors and 
economic burden in different countries around the world [11]. In this paper we report the population 
estimate of COPD prevalence in Sousse, Tunisia, using the BOLD protocol.  
2. Experimental Section 
We followed the BOLD protocol as it has been described elsewhere [11,12]. Data were collected by 
trained and certified staff, under continuous quality control from the BOLD coordinating center. 
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2.1. Participants 
The survey was conducted on a gender-stratified representative random sample of non-institutionalized 
residents selected from the general population living in the urban area of Sousse. Two quartiers with 
clear administrative boundaries were selected for convenience and districts were sampled at random 
from each of the two selected quartiers. Site or home visits were scheduled for adults aged ≥40 years 
to complete questionnaires and perform pre- and post-bronchodilator spirometry. All participants gave 
written informed consent, and the study was approved by the Medical School of Sousse Ethics’ 
Committee. 
2.2. Data Collection 
2.2.1. Study Outcomes 
Spirometry was performed according to ATS (American Thoracic Society) criteria [13,14] before 
and 15–60 min after administering 200 µg of salbutamol (Ventolin, GlaxoSmithKline, Middlesex, 
UK). Portable spirometers (Easy One ndd. Medizintechnik, Zurich, Switzerland) were used in this 
study and were daily calibrated, using a 3.00 L syringe. All spirometry data were reviewed and graded 
for quality by the BOLD Pulmonary Function Quality Control Centre. We defined COPD according to 
GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria, as post-bronchodilator 
FEV1/FVC (FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity) less than 70% [15]. 
2.2.2. Definition of COPD Stages 
COPD stages in those with post-bronchodilator (post-BD) FEV1/FVC <0.7, were defined according 
to GOLD guidelines: Stage I: if FEV1 ≥80% predicted; Stage II: if FEV1 ≥50 and <80% predicted; 
Stage III: if FEV1 ≥30 and <50%; and Stage IV: if FEV1<30% predicted. We used the third US 
National Health and Nutrition Examination Survey (NHANES 3) to compute predicted values for 
FEV1 [16]. We examined also the impact of using FEV1/FEV6 (FEV6: Forced expiratory volume in 6 s) 
in place of FEV1/FVC in our definitions
 
[17]. Doctor-diagnosed COPD was defined as self-reported 
physician’s diagnosis of COPD, chronic bronchitis, or emphysema.  
The number of pack-years of cigarette smoking was calculated as the average number of cigarettes 
smoked per day divided by 20, times the duration of smoking in years. 
Education level was assessed as self-reported years of education and classified according to  
the education system in Tunisia, as 0, 1–5, 6–8, 9–11 and >12 years. 
2.2.3. Questionnaire Data 
The questionnaires used in this study contained information on history of respiratory symptoms and 
diseases, use of respiratory medication, comorbidities, risk factors for COPD, health-care utilization, 
tobacco exposure, use of biomass fuels for cooking or heating, occupational exposures and activity 
limitation due to breathing problems [11]. 
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2.3. Statistical Analysis 
Population estimated prevalence of COPD was calculated for the overall Sousse population, using 
population weights. Prevalence of COPD was stratified by gender, age and pack-years of  
cigarette smoking.  
The significance of differences between proportions was determined by chi-square tests. Calculations 
of odd ratios (ORs) and 95% CI values for COPD in relation to potential risk factors were performed 
with multivariate logistic regression models. The variables of sex, age groups, body mass index (BMI), 
smoking status, pack-years of smoking, occupational exposure to dusts/gases/fumes, respiratory disease 
in family, pulmonary problems in childhood and education were tested in the multivariate logistic 
regression model. All statistical tests were performed with Stata statistical software (version 7.0; Stata 
Corporation, College Station, TX, USA), and a p value of 0.05 was considered significant.  
3. Results  
3.1. Sample Demographics 
Of the 807 subjects sampled from Sousse region in Tunisia, 717 were interviewed. The response 
rate was 90%. The number of non-responders and ineligible participants were 77 and 13, respectively. 
The reasons for non-response included refusals, contact failures, spirometry ineligibility, and failed 
attempts. 
Among the 717 interviewees, 56 failed to complete the spirometry testing and 661 completed 
acceptable and reproducible post-BD spirometry and questionnaires and were included in this analysis 
(Figure 1). There were no significant differences in age, sex and smoking status between responders 
and non-responders, thus, the pattern of these variables distribution was similar in the two groups, 
suggesting that the study participants are highly representative of the general population (data not 
shown).  
Figure 1. Response rate of questionnaire and spirometry. 
 
Sampled Subjects
(807)
Refusals or contact failure
9.5% (77/807)
Interviewed with 
questionnaire
90.4% (730/807)
Eligible for spirometry
88.8% (717/807)
Ineligible
1.6% (13/807)
Fail to complete 
spirometry
7.8% (56/717)
Complete  spirometry
81.9% (661/807)
Response (Acceptable spirometry (grade A or B) and questionnaire)
81.9% (661/807)
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The study sample consisted of 309 men and 352 women. The mean age of the final study 
population did not differ significantly between men and women. The educational level differs 
significantly between men and women (2.8 (SD, 1.23) vs. 1.9 (SD, 1.41); p < 0.01).  
A history of current or past smoking was greater in men than women (47.4% vs. 7.0% and 74.3% 
vs. 8.5%, respectively). Despite the differences in smoking history between men and women, percent 
of predicted FEV1 and FVC did not differ between sexes while FEV1/FVC was significantly higher in 
women (Table 1). 
Moreover, we used spirometric data to classify people with restricted spirometry (FEV1/FVC ≥ 0.70 
and FEV1 < 80%). Overall, we found that 12.6% of men (39/309) and 19% of women (67/352) had 
restricted spirometry. 
Table 1. Participants smoking status * and lung function ** by sex. 
 Men Women p-value 
Smoking status (pack years) 
<0.001 
Never 78 (19.6) 320 (80.4) 
0–10 22 (62.9) 13 (37.1) 
10–20 57 (87.7) 8 (12.3) 
20+ 152 (93.3) 11 (6.7) 
Lung Function  
FEV1 (L) 3.1 (0.77) 2.3 (0.60) <0.001 
FEV1 (%, predicted) 90.5 (17.34) 92.3 (17.10) 0.1913 
FVC (L) 4.0 (0.79) 2.8 (0.66) <0.001 
FVC (%, predicted) 89.3 (13.66) 88.7 (14.63) 0.5801 
FEV1/FVC (%) 77.8 (8.66) 81.9 (5.73) <0.001 
* Smoking pack-years are expressed in N (%); ** Lung function measures are taken post bronchodilator and 
are expressed in Mean (SD); Abbreviations: FEV1—1 s forced expiratory volume, FVC—forced vital 
capacity, SD—standard deviation. 
Table 2 shows the estimated prevalence of smoking in Tunisia by age and gender. 41.9% of  
the Tunisian population is estimated to be ever smokers, while the prevalence of current smoking in 
this population is estimated to be 28.6%. Current smokers accounted for 49.4% of the male subjects 
and 7.3% of the female subjects. 
According to GOLD diagnostic criteria, the overall prevalence of stage I or higher COPD was 7.8% 
(1.2) (Lower Limit of Normal (LLN) modified stage I or higher COPD prevalence was 5.3% (1.4)). 
The prevalence of COPD was significantly higher in men than in women (13.5% (2.9) vs. 1.9% 
(0.7) respectively; p < 0.01). The prevalence of GOLD stage II COPD was 4.2% (0.9) (LLN modified 
stage II COPD prevalence was 3.8% (1.3)) and was also different between men and women (7% (1.9) 
vs. 1.2% (0.7) respectively; p < 0.01) (Figure 2). However, none of the study subjects met criteria for 
GOLD stages III or IV COPD. The prevalence of COPD stage I and stage II increased with age in both 
sexes, and for each age group was greater in men than in women (p < 0.01) (Figure 2). 
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Table 2. Population estimates of the smoking distribution in Sousse, Tunisia, by age and gender *. 
 40–49 year 50–59 year 60–69 year 70+ year All 
Male gender      
Never smoker 24.3 (6.7) 23.5 (3.5) 34.4 (5.4) 25.0 (7.2) 25.8 (4.1) 
Former smoker 16.0 (3.6) 26.9 (4.0) 42.0 (6.2) 37.6 (7.7) 24.8 (3.0) 
Current smoker 59.6 (5.8) 49.6 (4.8) 23.6 (3.8) 37.5 (7.8) 49.4 (4.2) 
Female gender      
Never smoker 89.4 (3.2) 90.7 (3.0) 96.2 (2.8) 95.2 (4.7) 91.3 (2.1) 
Former smoker 1.5 (1.0) 2.8 (1.6) 0 0 1.5 (0.7) 
Current smoker 9.2 (2.8) 6.5 (2.1) 3.8 (7.8) 4.8 (4.7) 7.3 (1.9) 
Total      
Never smoker 57.1 (4.6) 54.9 (3.1) 64.6 (3.5) 64.2 (5.6) 58.1 (2.8) 
Former smoker 8.7 (2.0) 15.6 (2.1) 21.5 (3.5) 16.6 (3.7) 13.3 (1.4) 
Current smoker 34.2 (4.1) 29.5 (3.2) 13.9 (2.5) 19.2 (4.8) 28.6 (2.9) 
* All values are % (SE); Abbreviations: SE—standard error.  
Figure 2. Prevalence of COPD (GOLD stage I and II COPD) by gender and age groups. 
 
COPD: Chronic Obstructive Pulmonary Disease; GOLD I: Global Initiative for Chronic Obstructive Lung 
Disease Stage I COPD; GOLD II: Global Initiative for Chronic Obstructive Lung Disease Stage II COPD;  
* p < 0.01, significant difference between men and women according to age. 
Our study showed that 74.5% of patients with COPD (94.7% of male and 5.2% of female patients 
with COPD) were smokers. As expected, prevalence of COPD (GOLD stage I and higher) increased 
with increasing pack-years of cigarette smoking in both men and women from 3.9% in subjects who 
had never smoked to 16.1% in those with a smoking history ≥20 pack-years. Similarly, the prevalence 
of GOLD stage II COPD increased from 2.6% in subjects who had never smoked to 8.2% in those with 
the most pack-years of smoking (Figures 3 and 4). Surprisingly, high prevalence of COPD stages I and II 
was found in never-smokers and especially in men (12.4 % (6.7) and 9.3% (5.4), for stages I and II 
respectively; p < 0.01) (Figures 3 and 4). 
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Figure 3. Prevalence of GOLD Stage I and higher by pack years and sex. 
 
GOLD I: Global Initiative for Chronic Obstructive Lung Disease Stage I COPD; * p < 0.01, significant 
difference between men and women according to smoking status. 
Figure 4. Prevalence of GOLD Stage II by pack years and sex. 
 
GOLD II: Global Initiative for Chronic Obstructive Lung Disease Stage II COPD; * p < 0.01, significant 
difference between men and women according to smoking status. 
3.2. Risk Factors for COPD 
We performed univariate and multivariate logistic regression to assess the association of COPD with 
gender, age, education, smoking history, BMI, childhood and family history of respiratory disease and 
occupational exposure to dust. After mutual adjustment for all these potential factors in the model, we 
found that in our study population, COPD was more common in subjects aged 70+ years (OR = 17.67,  
p = 0.007) compared to subjects aged 40–49 years of age, and in those with a BMI < 20 kg/m2  
(OR = 6.61, p = 0.02) compared to subjects with a BMI of 20–25 kg/m2. Smoking 10+ pack years  
per year, was independently associated with an increased risk of COPD (OR = 1.25, p = 0.003), however 
that association decreased and did not reach conventional levels of statistical significance (OR = 1.18,  
p = 0.1) after adjustment of all other potential risk factors in the model (Table 3). 
  
p < 0.01
p < 0.01
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Table 3. Factors associated with COPD *. 
 Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) ** p-value 
Sex    
Male 1  1  
Female 0.198 (0.062–0.635) 0.010 0.201 (0.015, 2.733) 0.210 
Age, years    
40–49 1  1  
50–59 2.090 (0.769–5.677) 0.137 2.105 (0.755, 5.863) 0.142 
60–69 2.472 (0.778–7.853) 0.116 3.519 (0.942, 13.152) 0.060 
≥70 10.403 (2.072–52.222) 0.007 17.670 (2.488, 125.472) 0.007 
Education, years    
0 1  1  
1–5 0.375 (0.076–1.840) 0.208 0.480 (0.062, 3.698) 0.455 
6–8 0.774 (0.211–2.844) 0.681 1.471 (0.245, 8.827) 0.653 
9–11 0.798 (0.329–1.934) 0.595 0.932 (0.112, 7.761) 0.944 
≥12 0.602 (0.142–2.545) 0.464 0.881 (0.273, 2.839) 0.820 
Smoking Status    
Never smoker 1    
Former smoker 2.164 (0.667, 7.022) 0.182 0.426 (0.041, 4.429) 0.449 
Current smoker 3.301 (1.127, 8.150) 0.030 0.641 (0.084, 4.885) 0.648 
Smoking pack-years    
10 year increase 1.252 (1.093–1.435) 0.003 1.176 (0.941, 1.470) 0.141 
Body Mass Index    
<20 4.673 (1.032, 21.159) 0.046 6.610 (1.439, 30.354) 0.019 
20–25 1  1  
25–30 0.536 (0.145, 1.977) 0.324 0.821 (0.267, 2.527) 0.714 
30–35 0.743 (0.282, 1.960) 0.524 1.299 (0.401, 4.208) 0.642 
>35 0.271 (0.069, 1.063) 0.060 0.660 (0.177, 2.466) 0.512 
Occupational dust exposure    
10 year increase 1.288 (0.978, 1.697) 0.069 0.996 (0.689, 1.441) 0.983 
Childhood breathing problems    
No 1  1  
Yes 0.956 (0.099, 9.242) 0.967 1.666 (0.195, 14.235) 0.620 
Family history of pulmonary disease    
No 1  1  
Yes 0.190 (0.024, 1.508) 0.108 0.194 (0.018, 2.114) 0.164 
* Post-bronchodilator FEV1/FVC < Lower Limit of Normal (LLN) defined COPD; ** Mutual adjustment for 
all the risk factors in the table; Abbreviations: CI = confidence interval; COPD = chronic obstructive 
pulmonary disease; OR = odds ratio. 
3.3. Lifetime Diagnosis of COPD and Respiratory Symptoms 
The prevalence of self-reported doctor-diagnosed chronic bronchitis, emphysema or COPD was 
3.5% (0.7). This value is half of the estimated prevalence of GOLD stage I or higher COPD in Sousse 
(7.8%) (Table 4). The prevalence of self-reported doctor-diagnosed COPD was higher in females than 
males (4.8% (0.9) vs. 2.3% (0.8), respectively). 
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The prevalence of doctor-diagnosed COPD increased with age, particularly in men as seen in Table 4 
but no clear trend was seen with increasing pack-years of smoking. 
Table 4. Prevalence of COPD according to Doctor Diagnosis’s by; gender, age and pack years *. 
 Doctor-Diagnosed COPD 
 Male Female Total 
Age, year%    
40–49 1.1 (0.7) 4.6 (1.5) 2.8 (0.9) 
50–59 2.4 (1.4) 7.0 (1.9) 4.6 (1.4) 
60–69 3.2 (2.5) 3.8 (2.8) 3.5 (2.4) 
70+ 9.4 (6.8) 0 4.1 (3.0) 
All 2.3 (0.8) 4.8 (0.9) 3.5 (0.7) 
Pack-Years%    
Never-smoker 3.3 (1.5) 4.2 (0.9) 4.0 (0.8) 
0–10  0 6.2 (5.7) 2.0 (2.0) 
10–20  3.3 (2.5) 19.8 (17.2) 5.3 (3.4) 
20+  1.8 (0.9) 9.2 (7.2) 2.3 (0.8) 
Total  2.3 (0.8) 4.8 (0.9) 3.5 (0.7) 
* All values are % (SE). 
The prevalence of cough, sputum, wheezing, and breathlessness in patients with COPD Stages I and II 
are shown in Table 5. The frequency of these respiratory symptoms increased with the severity of 
COPD. Only 2.7% of the subjects had ever been tested by lung function tests (spirometry). 
Table 5. Frequencies of respiratory symptoms in patients with chronic obstructive pulmonary disease. 
 COPD defined as 
 LLN Stage I+ 
(n = 33) 
LLN Stage II 
(n = 30) 
GOLD Stage I+ 
(n = 51) 
GOLD Stage II 
(n = 39) 
Cough 13 (39.39) 13 (43.33) 19 (37.25) 17 (43.59) 
Sputum 18 (54.55) 17 (56.67) 25 (49.02) 22 (56.41) 
Wheezing 20 (60.61) 20 (60.67) 25 (49.02) 22 (56.41) 
Dyspnea 12 (36.36) 12 (40.00) 16 (31.37) 16 (41.03) 
Chronic cough with phlegm † 7 (21.21) 7 (23.33) 10 (19.61) 9 (23.08) 
Values are n (%). Definition of abbreviations: COPD = chronic obstructive pulmonary disease; GOLD = 
Global Initiative for Chronic Obstructive Lung Disease; LLN = Lower Limit of Normal; † Cough with 
phlegm for at least 3 months per year in the previous 2 years. 
4. Discussion  
The key findings of this population-based prevalence survey are that 7.8% of the residents of 
Sousse, Tunisia, 40 years of age or over had at least Stage I COPD, and this was more common in men 
than in women. These findings indicated COPD as a more serious public health problem in Tunisia 
than expected from previous studies [3] and illustrate the magnitude of the burden that COPD will 
pose in the near future, as the proportion of the population living into old age when chronic diseases 
including COPD are common. 
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Our finding is consistent with an expected range of 4% to 10% from an international review of 
COPD prevalence based on spirometry [8,18,19]. As expected, COPD prevalence found in our study 
most likely reflects the aging of our study population. This is similar to the results found in many other 
countries using the same BOLD methodology [14] and in many other previous epidemiological  
studies [19,20]. Indeed, the projected increase in the prevalence of COPD worldwide is being driven 
more by the projected aging of the world population than by estimated changes in the prevalence of 
smoking [21]. Demonstrating this point, our data show a steep gradient in COPD prevalence with 
increasing age, with the highest prevalence seen in men and women ≥70 years of age. This result 
reflects the use of the threshold based on a fixed ratio of less than 0.70 to define irreversible airflow 
obstruction as recommended by the GOLD. Indeed, the fixed ratio has been shown to overdiagnose 
airflow obstruction, especially in the elderly since it has a small but significant age-related  
regression [17,22,23]. 
The finding that COPD prevalence increased with age does not minimize the fact that smoking is an 
important risk factor for COPD [4,24,25]. In the present study, smoking 10+ pack years per year, was 
independently associated with an increased risk of COPD.  
However it is surprising that in the present study, half of patients with COPD (50%) were never 
smokers. The prevalence of COPD in never smokers, which was as high as 3.9%, was much higher in 
comparison to other countries participating in the BOLD Study [14] and suggested that factors other 
than smoking exposure might also be involved in COPD. 
Moreover, the potential risk factors we explored were not associated with having more COPD (i.e., 
exposure to occupational dust) suggesting that other factors that were not explored on our model 
should be considered. There is a lot of debate in the current literature whether exposure to biomass 
cooking may be a risk factor for COPD, particularly in low income settings, however the evidence  
is contradictory [26].  
As reported in the study of Lamprecht et al., we found a consistent association of airflow obstruction 
in never smokers with asthma and older age [27]. Similar results were found in two other cross-sectional 
studies that showed that COPD in never smokers was more common in older subjects with a medical 
diagnosis of asthma and with a low educational level [27,28]. Other studies [29,30] are consistent with 
our finding and have found that persons who could have or have had an asthma will be progressed into 
chronic obstruction. Thus, asthma has been identified as a risk factor of COPD [30]. 
In Tunisia, the COPD prevalence in women is lower than that seen in men. This situation is 
probably due to the fact that Tunisian women have not been as likely to smoke as men. This situation 
is different in some developed countries, where the prevalence of smoking in women is now often as 
high as that in men [19]. There has been considerable controversy as to whether women are at equal or 
perhaps at greater risk than men given an equal exposure. This controversy has not been resolved, 
although there is increasing evidence that women may be more vulnerable [21]. In developing 
countries, the increase in smoking among women, that is likely to occur, will probably lead to a tidal 
wave of COPD as women both have more exposure and live longer. Women are also more likely than 
men to be exposed to high indoor air pollution levels in developing countries. Thus, fossil fuel 
pollution has been found to have a greater effect in women compared with men [31,32].  
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Surprisingly, we found that a low BMI is associated with having more COPD, and why this should 
be the case and whether other related factors such as nutrition could explain this finding, warrants 
further investigation. 
Our results revealed only 3.5% of participants which reported doctor-diagnosed COPD.  
An important finding of our study is that there was a huge gap between physician diagnosis of COPD 
and the presence of airflow obstruction defined by spirometry. Moreover, more than 87.9% had never 
been diagnosed before this survey. This suggests that diagnosis of COPD based on symptoms may not 
be adequate and awareness of COPD among health professionals require more use of objective 
measures of lung function to confirm the diagnosis. 
Prevalence estimates depend on the diagnostic criteria and methods used [33]. In order to obtain 
accurate estimates of COPD prevalence, we used standardized methods developed by the BOLD 
initiative [13] that incorporate many quality control measures, including careful population-based 
sampling with high response rate, standardized spirometry equipment, central training, certification, 
and monitoring of technicians, over reading of all spirograms and a strict protocol for the translation of 
questionnaires. 
Estimated population frequency of COPD in Stage ≥1 in our study was very high in subjects aged 
70 or more (about 61.5% in men and over 12.5% in women). Using a post-bronchodilator fixed 
FEV1/FVC ratio of less than 0.7 as a threshold for COPD diagnosis in this age group can probably 
lead to overestimation of the disease prevalence. Indeed, the limitations of using a fixed FEV1/FVC 
ratio <0.70 as a cut point for airflow obstruction, as recommended by the GOLD, have been 
highlighted recently [22,34,35] and this use has the potential to misclassify at older ages, since  
the ratio has a small but significant age-related regression [22]. The present controversy revolves 
around the question of whether using a fixed ratio of FEV1/FVC or a more statistically appropriate 
metric, such as the lower limit (e.g., 95th percentile) of the population distribution is a better way to 
separate normal aging from abnormal aging (i.e., disease). A population-based study in individuals 
over 70 years showed FEV1/FVC ratio below 0.7 in about 35% of asymptomatic, non-smoking 
subjects [6]. Study based on the NHANES III data has shown that up to 20% of elderly subjects with 
FEV1/FVC above 5th percentile had FEV1/FVC ratio below 0.7 [35]. 
The LLN, based on the normal distribution, classify the bottom 5% of the healthy population as 
abnormal. When we use LLN criterion in the evaluation of FEV1/FVC, it could be one of alternatives 
to minimize the potential misclassification [15,36]. Several previous studies showed that use of  
the LLN criterion instead of the fixed ratio criterion minimizes known age biases and better reflects 
clinically significant irreversible airway obstruction [22,35]. 
Compared to the reports on COPD prevalence using the same methods [8,37,38], our data showed  
a lower prevalence of COPD in Tunisia than that in the five Latin American cities [8], in South Africa [37] 
and in Turkey [38]; indeed, GOLD Stage II COPD, constituted about half of all the COPD cases  
(4.2% overall; 7.0% in men and 1.2% in women). 
The high prevalence of GOLD Stage II COPD in our population could probably be attributed to  
the fact that all the measured FEV1 and FVC values were expressed relative to the NHANES III white 
American references values; however, the Tunisian spirometry reference values are 10% lower than 
Caucasians and the latter may result in an over-diagnosis of GOLD Stage II COPD [39]. 
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5. Conclusions 
The results of BOLD Study carried out in Tunisia confirm the high prevalence of COPD and call 
for more research to be directed toward preventive measures and efforts. In fact, smoking cessation 
and early diagnosis may inhibit the growth to a relevant clinical stage. Therefore, health-care 
professionals are duty to do more researches, to inform patients about the disease and to advise them to 
reduce and even halt smoking. Hence, the outbreak of COPD may be monitored. 
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